Sorry, you need to enable JavaScript to visit this website.

Venture Investments

marie-clarie.jpg

Marie-Claire Peakman, MRPHARMS, PHD

Marie-Claire Peakman, MRPHARMS, PHD is a Partner at Pfizer Ventures and Executive Director, Worldwide Business Development. Marie-Claire is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. She currently has responsibility for Pfizer’s investments in Curve Therapeutics, DEM Biopharma, Grey Wolf Therapeutics, Mozart Therapeutics, Normunity and TRIMTECH Therapeutics. She is an observer on the boards for Capstan Therapeutics, Crossbow Therapeutics, Mediar Therapeutics and TRex Bio.

Marie-Claire brings over 25 years of experience at Pfizer, leading platform technology groups that support small molecule programs from idea to development candidate selection across all therapeutic areas. These teams, including the Primary Pharmacology Group which she founded in 2009, played key roles in the identification of Paxlovid™ (nirmatrelvir), Cibinqo™ (abrocitinib), Litfulo™ (ritlecitinib) and multiple other small molecules currently in the clinic. Her experience extends to compound management, high throughput ADME, data support and management, genetically modified models, bioimaging and biobanking. Prior to Pfizer Marie-Claire gained experience at The Wellcome Foundation, at Guy’s Hospital, London, UK and held postdoctoral positions at Yale University. She is a member of the advisory board for Connecticut Bioscience Innovation Fund and has multiple roles on non-profit boards in the community.

Marie-Claire received a B.Pharm.Hons. degree in Pharmacy and a Ph.D. in Physiology & Pharmacology from the University of Nottingham U.K. She is a member of the Royal Pharmaceutical Society.

Email: [email protected]

Other People In Venture Investments

Media Name: Rana 300x170.jpg
Rana Al-Hallaq, PHD

Executive Director, WWBD / Partner

mbaran2025_300x170.webp
Michael Baran, MBA, PHD

Executive Director, WWBD / Partner

headshot of boyoon choi
Boyoon Choi

Senior Corporate Counsel

Michael Diem headshot thumbnail
Michael C. Diem, MD

Vice President, WWBD / Senior Managing Partner

irena_melnickova_300x170.jpg
Irena Melnikova, PHD

Executive Director, WWBD / Partner

Andrew Muratore headshot thumbnail
Andrew J. Muratore

Vice President & Chief Counsel, Strategic Partnership & Investments

Media Name: Chris 300x170.png
Christopher O’Donnell, PHD

Vice President, WWBD / Partner

Denis headshot thumbnail
Denis Patrick, PHD

Vice President, WWBD / Partner

Luis Vargas headshot thumbnail
Luis Vargas

Finance Director, Business Development Reporting & Analytics

Sophia Wood headshot thumbnail
Sophia Wood

Executive Assistant

Venture Investments

marie-clarie.jpg

Marie-Claire Peakman, MRPHARMS, PHD

Marie-Claire Peakman, MRPHARMS, PHD is a Partner at Pfizer Ventures and Executive Director, Worldwide Business Development. Marie-Claire is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. She currently has responsibility for Pfizer’s investments in Curve Therapeutics, DEM Biopharma, Grey Wolf Therapeutics, Mozart Therapeutics, Normunity and TRIMTECH Therapeutics. She is an observer on the boards for Capstan Therapeutics, Crossbow Therapeutics, Mediar Therapeutics and TRex Bio.

Marie-Claire brings over 25 years of experience at Pfizer, leading platform technology groups that support small molecule programs from idea to development candidate selection across all therapeutic areas. These teams, including the Primary Pharmacology Group which she founded in 2009, played key roles in the identification of Paxlovid™ (nirmatrelvir), Cibinqo™ (abrocitinib), Litfulo™ (ritlecitinib) and multiple other small molecules currently in the clinic. Her experience extends to compound management, high throughput ADME, data support and management, genetically modified models, bioimaging and biobanking. Prior to Pfizer Marie-Claire gained experience at The Wellcome Foundation, at Guy’s Hospital, London, UK and held postdoctoral positions at Yale University. She is a member of the advisory board for Connecticut Bioscience Innovation Fund and has multiple roles on non-profit boards in the community.

Marie-Claire received a B.Pharm.Hons. degree in Pharmacy and a Ph.D. in Physiology & Pharmacology from the University of Nottingham U.K. She is a member of the Royal Pharmaceutical Society.

Email: [email protected]

Other People In Venture Investments

Media Name: Rana 300x170.jpg
Rana Al-Hallaq, PHD

Executive Director, WWBD / Partner

mbaran2025_300x170.webp
Michael Baran, MBA, PHD

Executive Director, WWBD / Partner

headshot of boyoon choi
Boyoon Choi

Senior Corporate Counsel

Michael Diem headshot thumbnail
Michael C. Diem, MD

Vice President, WWBD / Senior Managing Partner

irena_melnickova_300x170.jpg
Irena Melnikova, PHD

Executive Director, WWBD / Partner

Andrew Muratore headshot thumbnail
Andrew J. Muratore

Vice President & Chief Counsel, Strategic Partnership & Investments

Media Name: Chris 300x170.png
Christopher O’Donnell, PHD

Vice President, WWBD / Partner

Denis headshot thumbnail
Denis Patrick, PHD

Vice President, WWBD / Partner

Luis Vargas headshot thumbnail
Luis Vargas

Finance Director, Business Development Reporting & Analytics

Sophia Wood headshot thumbnail
Sophia Wood

Executive Assistant